ArriVent BioPharma (AVBP) Change in Acquisitions & Divestments (2025 - 2026)

ArriVent BioPharma (AVBP) reported Change in Acquisitions & Divestments of $68.0 million for Q1 2026, up 45.73% on a YoY basis from $46.6 million in Q1 2025, and down 15.02% sequentially from $80.0 million in Q4 2025.

ArriVent BioPharma (AVBP) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends

ArriVent BioPharma (AVBP) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $68.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 45.73% year-over-year to $68.0 million; the trailing twelve-month figure through Mar 2026 stood at $223.0 million (changed N/A YoY), and the FY2025 full-year result was $201.7 million, up 11772.04% from the prior year.
  • Change in Acquisitions & Divestments slipped to $68.0 million in Q1 2026, from $80.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $80.0 million in Q4 2025 to a low of $35.5 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 ArriVent BioPharma 1.37 Bn 1.37 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 67.97 Mn
Mar 31, 2026 67.97 Mn
Dec 31, 2025 79.98 Mn
Dec 31, 2025 79.98 Mn
Sep 30, 2025 39.61 Mn
Sep 30, 2025 39.61 Mn
Jun 30, 2025 35.48 Mn
Jun 30, 2025 35.48 Mn
Mar 31, 2025 46.64 Mn
Mar 31, 2025 46.64 Mn